Influence of polymorphism (RFLP-sstI) at the apolipoprotein C-III gene locus on the lipoprotein metabolism and insulin resistance in essential hypertensive patients. Interaction between gender and genetic polymorphism

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 13, Issue 4, 2003, Pages 194-201

  Espino Montoro, A ^a   Barrios Artillo, M ^a   Lopez Chozas J M ^a   Cayuela, A ^b   Stiefel, P ^b   Villar, J ^b  

^a De la Merced University Hospital ^*  (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

APOC3; Apolipoprotein C III; Cholesterol; Gender; Genetic polymorphism; Hypertension; RFLP Ssti; S1 allele; S2 allele; Tryglicerides

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; CHOLESTEROL; GLUCOSE; INSULIN; APOLIPOPROTEIN C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE MONITORING; BODY MASS; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYMATIC ASSAY; ESSENTIAL HYPERTENSION; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOCHEMISTRY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LABORATORY TEST; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RADIOIMMUNOASSAY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEX ROLE; ULTRACENTRIFUGATION; BLOOD; GENDER IDENTITY; GENETIC POLYMORPHISM; GENETICS; HYPERTENSION; METABOLISM; MIDDLE AGED;

ADULT; APOLIPOPROTEIN C-III; APOLIPOPROTEINS B; APOLIPOPROTEINS C; BLOOD GLUCOSE; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; GENDER IDENTITY; HUMANS; HYPERTENSION; INSULIN; INSULIN RESISTANCE; LIPOPROTEINS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; TRIGLYCERIDES;

EID: 1542494200     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-4753(03)80011-X     Document Type: Article

References (50)

1. Reaven CM (1992) The role of the insulin resistance and hyperinsulinemia in coronary heart disease. Metabolism 41 (suppl): 16-19
2. DeFronzo RA, Ferrannini E (1991) Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 14: 173-194
3. Villar J, Muñiz O, Stiefel P, Miranda ML, Jiménez L, Montilla C, Martín-Sanz V, Carneado J (1993) Influencia de la hiperinsulinemia en el perfil dislipémico de la hipertension arterial. Med Clin (Bare) 103: 241-245
4. Després JP, Lamarche B, Mauriège P, Cantin B, Dagenais GR, Moorjani S, et al (1996) Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334: 952-957
5. Moller DE, Bjorbaek C, Vidal-Puig A (1996) Candidate genes for insulin resistance. Diabetes Care 19: 396-400
6. Tas S, Abdella NA (1994) Blood pressure, coronary artery disease, and glycaemic control in type 2 diabetes mellitus: relation to apolipoprotein-CIII gene polymorphism. Lancet 343: 1194-1195
7. Ordovas JM, Civeira F, Genest J Jr, Craig S, Robbins AH, Meade T, et al (1991) Restriction fragment length polymorphisms of the apolipoprotein A-I, C-III, A-IV gene locus. Atherosclerosis 87: 75-86
8. Tybjaerg-Hansen A, Nordestgaard BG, Gerdes LU, Faergeman O, Humphries SE (1993) Genetic markers in the apo AI-CIII-AIV gene cluster for combined hyperlipidemia, hypertriglyceridemia, and predisposition to atherosclerosis. Atherosclerosis 100: 157-169
9. Surguchov AP, Page GP, Smith L, Patsch W, Boerwinkle E (1996) Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia. Arterioscler Thromb Vasc Biol 16: 941-947
10. Tas S (1991) Genetic predisposition to coronary heart disease and gene for apolipoprotein C-III. Lancet 337: 113-114
11. De Lorenzo F, Rubba P, Monticelli A, Cocozza S (1993) Coronary heart disease, echo-Doppler evidence of peripheral arterial disease and polymorphism of apolipoprotein B gene and apo A-I/C-III cluster. Angiology 44: 785-790
12. Shoulders CC, Harry PJ, Lagrost L, White SE, Shah NF, North JD, et al (1991) Variation at the apo AI/C-III/A-IV gene complex is associated with elevated plasma levels of apo CIII. Atherosclerosis 87: 239-247
13. Dammerman M, Sandkiujl LA, Halaas JL, Chung W, Breslow JL (1993) An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′-untranslated region polymorphisms. Proc Natl Acad Sci USA 90: 4562-4566
14. Hegele RA, Connelly PW, Hanley AJ, Sun F, Harris SB, Zinman B (1997) Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins. Arterioscler Thromb Vasc Biol 17: 2753-2758
15. Patsch W, Sharret AR, Chen IY, Lin-Lee YC, Brown SA, Gotto AM Jr, Boerwinkle E (1994) Associations of allelic differences at the A-I/C-III/A-IV gene cluster with carotid artery intima-media thickness and plasma lipid transport in hypercholesterolemic-hypertriglyceridemic humans. Atheroscler Thromb 14: 874-883
16. Breslow JL (1995) Familial disorders of high density lipoprotein metabolism. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds), The metabolic basis of inherited disease. McGraw-Hill, New York, pp 1251-1266
17. McConathy WJ, Gesquiere JC, Bass H, Tartar A, Fruchart JC, Wang CS (1992) Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J Lipid Res 33: 995-1003
18. Ginsberg HN, Le NA, Golberg IJ, et al (1986) Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins C-III and A-I. Evidence that apolipoprotein C-III inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J Clin Invest 78: 1287-1295
19. Aalto-Setälä K, Fisher EA, Chen X, Chajek-Shault T, Hayek T, Zecchner R, et al (1992) Mechanism of hypertriglyceridemia in human apolipoprotein (apo) C-III transgenic mice: diminished very low density lipoprotein fractional catabolic rate associated with increased apo C-III and reduced apo E on the particles. J Clin Invest 90: 1889-1900
20. Bruns GA, Karathanasis SK, Breslow JL (1984) Human apolipoprotein A-I/C-III gene complex is located on chromosome 11. Arteriosclerosis 4: 97-102
21. Humphries SE (1988) DNA polymorphisms of the apolipoprotein genes. Their use in the investigation of the genetic component of hyperlipidemia and atherosclerosis. Atherosclerosis 72: 89-108
22. Benlian P, Boileau C, Loux N, Pastier D, Masliah J, Coulon M, et al (1991) Extended haplotypes and linkage disequilibrium between II markers at the apo A1-C3-A4 gene cluster on chromosome 11. Am J Hum Genet 48: 903-910
23. Xu CF, Nanjee MN, Savill J, Talmud PI, Angelico F, Del Ben M, et al (1990) Variation at the apolipoprotein A-I/C-III/A-IV gene cluster and apo B gene loci is associated with lipoprotein and apolipoprotein levels in Italian children. Am J Hum Genet 47: 429-439
24. Cole SA, Szathmry E, Ferrell RE (1989) Gene and gene-product variation in the apolipoprotein A-I/C-III/A-IV cluster in the Dogrib Indians of the Northwest Territories. Am J Hum Genet 44: 835-843
25. Ito Y, Azrolan N, O'Connell A, Walsh A, Breslow JL (1990) Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science 249: 790-793
26. Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J (1994) Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem 269: 23610-23616
27. Stiefel P, Montilla C, Muñiz-Grijalvo O, Garcia-Lozano R, Alonso A, Miranda ML, Pamies E, Villar J (2001) Apolipoprotein E gene polymorphism is related metabolic abnormalities, but does not influence erythrocyte membrane lipid composition or sodium-lithium countertransport activity in essential hypertension. Metabolism 50: 157-160
28. Terpstra AH, Woodward CJ, Sanchez-Muñiz FJ (1981) Improved techniques for the separation of serum lipoproteins by density gradient ultracentrifugation: visualization by prestaining and rapid separation of serum lipoproteins from small volumes of serum. Anal Biochem 111: 149-157
29. Bucolo G, David H (1973) Quantitative determination of serum triglycerides by use of enzymes. Clin Chem 19: 476-482
30. Allain CC, Poon LS, Chang CSG, Richmond W, Fu PC (1974) Enzymatic determination of total serum cholesterol. Clin Chem 20: 470-475
31. Riepponen P, Marniemi J, Rautaoja T (1987) Immunoturbidimetric determination of apolipoprotein A-I and B in serum. Scand J Clin Lab Invest 47: 739-744
32. Catt KJ, Traeger GW (1967) Solid-phase radioimmunoassay in antibody coated tube. Science 158: 1570-1572
33. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Teacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and B cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28: 412-419
34. Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31: 545-548
35. Wilson PWF, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ (1994) Apolipoprotein E alleles, dyslipidemia and coronary heart disease. The Framingham Offspring Study. JAMA 272: 1666-1671
36. Aalto-Setälä K, Kontula K, Sane T, Nieminen M, Nikkilä E (1987) DNA polymorphism of apolipoprotein A-I/C-III and insulin genes in familial hypertriglyceridemia and coronary heart disease. Atherosclerosis 66: 145-152
37. Sidoli A, Giudici G, Soria M, Vergani C (1986) Restriction-fragment- length-polymorphisms in the AI-CIII gene complex occurring in a family with hypoalphalipoproteinemia. Atherosclerosis 62: 81-87
38. Rees A, Stocks J, Paul H, Ochuchi Y, Galton D (1986) Haplotypes identified by DNA polymorphisms at the apolipoprotein A-I and C-III loci and hypertriglyceridemia: a study in the Japanese population. Hum Genet 72: 168-171
39. Esterbauer H, Hell E, Krempler F, Patsch W (1999) Allele-specific differences in apolipoprotein C-III mRNA expression in human liver. Clin Chem 45: 331-339
40. Kaplan NM (1989) The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 149: 1514-1520
41. Salas J, Jansen S, López-Miranda J, Ordovás JM, Castro P, Marín C et al (1998) The SstI polymorphism of the apolipoprotein C-III gene determines the insulin response to an oral-glucose-tolerance test after consumption of a diet rich in saturated fats. Am J Clin Nutr 68: 396-401
42. Brunzell JD, Porte D, Bierman E (1979) Abnormal lipoprotein-lipase mediated plasma triglyceride removal in untreated diabetes mellitus associated with hypertriglyceridemia. Metabolism 28: 901-907
43. Li W, Dammerman M, Smith JD, Metzger S, Breslow JL, Leff T, et al (1995) Common genetic variation in the promoter of the human apo C-III gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 96: 2601-2605
44. Storlien LH, Pan DA, Kriketos AD, Baur LA (1993) High fat diet induced insulin resistance. Lessons and implications from animal studies. Ann N Y Acad Sci 683: 82-90
45. Steiner G (1991) Altering triglyceride concentrations changes insulin-glucose relationships in hypertriglyceridemic patients. Diabetes Care 14: 1077-1081
46. Randle PJ, Garland PB, Hales EA, Newsholme EA (1963) The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1: 785-789
47. Bjontorp P (1994) Fatty acids, hyperinsulinemia, and insulin resistance: which comes first. Curr Opin Lipidol 5: 166-174
48. Li WW, Todd L (1994) Regulation of apoCIII gene transcription by insulin: characterization of an insulin response element in the CIII promoter. Circulation 90: I.401.
49. Kessling A, Ouellette S, Bouffard O, Chamberland A, Betard C, Selinger E, et al (1991) Patterns of association between genetic variability in apolipoprotein (apo) B, apo AI-CIII-AIV, and cholesterol ester transfer protein gene regions and quantitative variation in lipid and lipoprotein traits: influence of gender and exogenous hormone. Am J Hum Genet 50: 92-106
50. William LW, Dammerman MM, Smith JD, Metzger S, Breslow JL, Leff T (1995) Common genetic variation in the promoter of the human apo CIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest 96: 2601-2605